

## Special Issue

# Resection Versus Transplant for Hepatocellular Carcinoma

### Message from the Guest Editor

Liver transplantation (LT) is, theoretically, the ideal treatment modality to prevent recurrence in patients with hepatocellular carcinoma (HCC). However, recurrence occurs even after LT, with poor patient prognosis. To avoid recurrence, several selection criteria have been reported for LT. Among these, the Milan criteria is the most well-known, first reported in 1996, later followed by many others with good survival outcomes. Liver resection (LR) is another curative treatment for patients with HCC. While recurrence also occurs after LR, repeat LR provides a good prognosis. Considering the above, the appropriate treatment modality for patients with HCC is not well-determined. This Special Issue aims to compare the treatment outcomes following LT and LR, welcoming original research articles and reviews on this topic.

---

### Guest Editor

Dr. Takashi Kokudo

Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery,  
Graduate School of Medicine, University of Tokyo, Tokyo, Japan

---

### Deadline for manuscript submissions

closed (30 April 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/214028](https://mdpi.com/si/214028)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)